Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly...

Published on 1 Nov 2024 on Benzinga · via Yahoo Finance

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year...

Read the rest of the article

Start tracking your investments with Statfolio

She has pledged to cut healthcare costs by implementing caps on prescription drug prices, such as...

Reuters · via Yahoo Finance 5 Nov 2024

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we ar...

Insider Monkey · via Yahoo Finance 4 Nov 2024

Recent data cited by Bloomberg reveals that deadly fungi, including Candida auris, have been...

Invezz 4 Nov 2024

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and ...

GuruFocus.com · via Yahoo Finance 1 Nov 2024

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year...

Benzinga · via Yahoo Finance 1 Nov 2024

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest mem...

WFMZ Eastern Pennsylvania and Western New Jersey 31 Oct 2024

As the company raises its dividend, that increase can more than offset the effects of inflation,...

The Motley Fool 31 Oct 2024

, opens new tab posted higher-than-expected third-quarter earnings on Thursday on strong sales of...

Reuters 31 Oct 2024

Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid...

Investing.com 31 Oct 2024

The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet.

Investor's Business Daily 31 Oct 2024